SYNJARDY XR (empagliflozin, metformin hydrochloride) by Boehringer Ingelheim is sodium-glucose transporter 2 inhibitors [moa]. Approved for sodium-glucose cotransporter 2 inhibitor [epc]. First approved in 2016.
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
SYNJARDY XR is a fixed-dose combination tablet containing empagliflozin (a sodium-glucose cotransporter 2 inhibitor) and metformin hydrochloride in extended-release formulation, approved by the FDA on December 9, 2016. It is indicated for the treatment of type 2 diabetes mellitus as an oral antidiabetic agent. The product combines two complementary mechanisms: empagliflozin increases urinary glucose excretion while metformin reduces hepatic glucose production and improves insulin sensitivity. SYNJARDY XR represents an extended-release convenience formulation of the original SYNJARDY combination, targeting patients requiring dual therapy with improved dosing convenience.
Sodium-Glucose Transporter 2 Inhibitors
Sodium-Glucose Cotransporter 2 Inhibitor
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
$278M Medicare spend — this is a commercially significant brand
Worked on SYNJARDY XR at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
SYNJARDY XR supports brand management, market access, and field sales roles within Boehringer Ingelheim's diabetes commercial organization, with responsibilities spanning formulary management, payer negotiations, and healthcare provider education. Key professional competencies include knowledge of type 2 diabetes treatment algorithms, SGLT2 inhibitor pharmacology, managed care dynamics, and the ability to differentiate extended-release convenience in a crowded combination therapy landscape. Currently, zero open positions are linked to SYNJARDY XR, indicating stable staffing or lower turnover on this mature product line.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo